Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Biotechnology Rebound Might Boost QQQS

BY | ETF Database
11/13/2024 | 71 VIEWS
Once stalwarts of the healthcare investing realm, biotechnology stocks and related ETFs have been laggards going back to 2021. That’s a lengthy run of disappointment that’s given some investors pause about embracing the space.Still, it’s hard to deny biotech’s history as an innovative growth industry. And it has the potential to improve both patient outcomes and portfolio performance. With those positives in mind, some investors may want to access biotech funds in nondedicated fashion. The Invesco NASDAQ Future Gen 200 ETF QQQS could be an idea to consider. QQQS allocates nearly half its weight to healthcare stocks. And in the conversation regarding the sector’s investment thesis, the Invesco ETF is pertinent because it’s a small-cap fund. And small-cap plus healthcare often equals biotech.QQQS Worth ConsideringTo its credit, QQQS has participated in the recent small-cap resurgence, gaining 14.29% over the 90 days ending Nov. 5. That could be the foundation of more extended upside should smaller biotech stocks break out of their now extended period of consolidation. “However, if you scroll back and look at the long-term charts, you can see that the way biotech behaves is quite unique. It tends to go through a boom and then consolidation, and then a boom and then consolidation,” noted Alisa Craig of Schroders. Looked at another way, it’s not surprising that biotech stocks have experienced a period of lethargy, but the current one is lengthy. That implies investors are waiting on the next big thing to stoke a new biotech boom. It’s up to the industry to deliver that catalyst. “These are actual things that have happened. There’s a lot of generalist money moves into the sector. There’s a lot of excitement because it’s a new market from nothing. That’s when you get these booms. The time period that you’ve just mentioned is from an end of a boom,” added Craig. Importantly, biotech valuations reset following the coronavirus vaccine boom. And should the Federal Reserve continue lowering interest rates in 2025, that could be another driver of upside for biotech equities and ETFs such as QQQS. Lower interest rates are pertinent to smaller biotech firms because many aren’t profitable and because their cash flows are longer-dated. “It’s not because these companies have debt. It’s because they are long-dated assets. So the revenues and profits that they expect to have are going to be 10, 15 years away. And when you value a company, you discount those cash flows from the future to today. And if the interest rate is bigger, that number is going to end up being smaller. It’s as simple as that,” concluded Craig. For more news, information, and analysis, visit the ETF Education Channel.

More Commentary

Active ETFs Offer Tax Perks, Too
BY | ETF Database
4:50 am ET 11/21/24 | 42 VIEWS
Sell on the Pop Prospects: November 20 Edition
BY | ETF Database
11/20/2024 | 20 VIEWS
The Case for Active Investing in 2025
BY | ETF Database
11/20/2024 | 57 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.

Copyright 1998–2024 FMR LLC. 
All rights reserved.